Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
595 studies found for:    Open Studies | "Ovarian Diseases"
Show Display Options
Rank Status Study
1 Not yet recruiting Value of MRI in the Characterization of Ovarian Masses Unable to Classify With Ultrasound Using the International Ovarian Tumor Analysis (IOTA) Simple Rules
Condition: Patients With a Sonographically Unclassifiable Adnexal Mass Using the IOTA Simple Rules
Intervention: Other: Diffusion/Perfusion-weighted Magnetic Resonance Imaging
2 Recruiting Mediterranean Diet Versus Hypocaloric Diet in PCOS
Condition: Polycystic Ovary Syndrome
Interventions: Other: mediterranean diet, restricted calorie;   Other: hypocaloric diet, restricted calorie
3 Recruiting Mediterranean Diet as Treatment for Normal Weight Women With PCOS
Condition: Polycystic Ovary Syndrome
Interventions: Other: mediterranean diet;   Other: normocaloric diet
4 Recruiting Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer
Intervention: Drug: BIBF 1120
5 Recruiting A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Insufficiency Patients
Conditions: Primary Ovarian Insufficiency;   Premature Ovarian Failure;   Infertility
Intervention: Biological: human amniotic epithelial cells (hAECs) transplantation
6 Not yet recruiting Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.
Conditions: Ovarian Neoplasms;   Fallopian Tube Neoplasms;   Peritoneal Neoplasms
Interventions: Drug: Part A: Dose Escalation of Cantrixil;   Drug: Part B: Expansion Cohort of Cantrixil;   Drug: Part C: Twice weekly dosing of Cantrixil
7 Recruiting Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients _MITO-23
Condition: Ovarian Neoplasms
Interventions: Drug: Trabectedin;   Drug: Pegylated Liposomal Doxorubicin;   Drug: Topotecan;   Drug: Gemcitabine;   Drug: Weekly Paclitaxel;   Drug: Carboplatin
8 Not yet recruiting Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Guadecitabine;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
9 Not yet recruiting Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
Condition: Epithelial Ovarian Cancer
Interventions: Drug: CC-486;   Biological: Pembrolizumab
10 Not yet recruiting MED-C Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Conditions: Neoplasms;   Lung Neoplasms;   Colon Neoplasms;   Breast Neoplasms;   Pancreatic Neoplasms;   Prostate Neoplasms;   Kidney Neoplasms;   Liver Neoplasms;   Rectal Neoplasms;   Hematologic Neoplasms;   Multiple Myeloma;   Myelodysplastic Syndromes;   Ovarian Neoplasms;   Bladder Neoplasms;   Testicular Neoplasms;   Endometrial Neoplasms;   Brain Neoplasms;   Biliary Tract Neoplasms;   Head and Neck Neoplasms;   Uterine Cervical Neoplasms;   Skin Neoplasms;   Melanoma;   Gastric Neoplasms;   Anal Neoplasms;   Sarcoma
Intervention: Other: Provider determined
11 Not yet recruiting Olaparib and Hsp90 Inhibitor AT13387 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Metastatic Solid Neoplasm;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Triple-Negative Breast Carcinoma;   Unresectable Solid Neoplasm
Interventions: Drug: Hsp90 Inhibitor AT13387;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Other: Pharmacological Study
12 Not yet recruiting Astronaut Vision Issues in a Ground Analog Population: Polycystic Ovary Syndrome
Conditions: Polycystic Ovarian Syndrome;   Idiopathic Intracranial Hypertension
Intervention:
13 Not yet recruiting Atezolizumab and Avastin in Late Recurrent Disease
Condition: Ovarian Cancer
Interventions: Drug: atezolizumab + avastin + platinum-based chemotherapy;   Drug: placebo + avastin + platinum-based chemotherapy
14 Not yet recruiting Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer
Condition: Recurrent Platinum Resistant Ovarian Cancer
Intervention: Drug: cediranib and olaparib
15 Not yet recruiting Bevacizumab in Ovarian Cancer Patients With Disease at Second-look Surgery
Conditions: Malignant Neoplasms of Female Genital Organs;   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
Intervention: Drug: Bevacizumab
16 Recruiting Study of Predictive Factors of Chemoresistance in Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Procedure: Cancer treatment
17 Recruiting Mobile Phone Technology to Increase Genetic Counseling
Condition: Ovarian Cancer
Intervention: Behavioral: mAGIC app
18 Not yet recruiting Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome
Condition: OHSS
Interventions: Drug: Cabergoline;   Drug: Calcium gluconate
19 Not yet recruiting A Phase II Study Of Nivolumab/ Bevacizumab
Conditions: Peritoneal Cancer;   Ovarian Cancer;   Fallopian Tube Cancer
Interventions: Drug: Bevacizumab;   Drug: Nivolumab
20 Not yet recruiting PET Imaging of Ovarian Carcinoma With 18F-FSPG
Conditions: Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Radiation: (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG);   Procedure: Positron Emission Tomography;   Other: Laboratory Biomarker Analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years